Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report)’s stock price reached a new 52-week low on Tuesday . The company traded as low as $24.17 and last traded at $24.3650, with a volume of 183470 shares. The stock had previously closed at $25.02.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on BRVE shares. TD Cowen initiated coverage on shares of Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating on the stock. Zacks Research raised shares of Braveheart Bio to a “hold” rating in a research note on Tuesday, September 1st. Wall Street Zen raised Braveheart Bio to a “hold” rating in a research note on Saturday, August 15th. Jefferies Financial Group began coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating and a $48.00 price target for the company. Finally, The Goldman Sachs Group assumed coverage on shares of Braveheart Bio in a report on Monday, August 31st. They issued a “buy” rating and a $48.00 price objective on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $45.25.
Get Our Latest Stock Analysis on BRVE
Braveheart Bio Stock Down 4.7%
Insider Buying and Selling at Braveheart Bio
In other news, Director Erez Chimovits acquired 1,940,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was acquired at an average price of $18.00 per share, with a total value of $34,920,000.00. Following the completion of the transaction, the director directly owned 11,901,826 shares in the company, valued at approximately $214,232,868. This represents a 19.47% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Christopher Viehbacher purchased 83,333 shares of the business’s stock in a transaction on Friday, August 7th. The stock was acquired at an average price of $18.00 per share, with a total value of $1,499,994.00. Following the completion of the acquisition, the director directly owned 609,519 shares in the company, valued at $10,971,342. The trade was a 15.84% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 8,751,942 shares of company stock worth $157,534,956.
About Braveheart Bio
We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.
Read More
- Five stocks we like better than Braveheart Bio
- Broadcom CEO Holds $350B Outlook Strong Amid Calls to Slow Froniter AI Development
- Microsoft’s 8% Dividend Hike: Confidence Signal or Distraction From Capex Math?
- Paramount Skydance Clears a Major Warner Bros. Discovery Hurdle—Here’s What Comes Next
- Can Apple Overtake NVIDIA as the World’s Most Valuable Company?
Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.
-ltd-logo-1200x675.png){kind=logo}
